ラグビー２ｃｈ

Because Javascript is disabled , there is the case that some of the functions can not be acquired or if the correct information that is not available . 検索 menu open About NU About NU Top University ProfilePresident's MessageFacts and FiguresLiving in NiigataBrochures / VideosEmploymentInformation Regarding the COVID-19 and Other Infectious Diseases Study at NU Study at NU Top Flow ChartDegree Programs (Undergraduate)Degree Programs (Graduate)Non-Degree Programs (Research Student)Non-Degree Programs (Exchange Student Program)Niigata University Short-term ProgramJapanese Language ProgramsFees / ScholarshipsStudent LifeCareer SupportSyllabus2024 Orientation for International Students Research Research Top FeatureResearch InstitutesCollaborationFind ResearchersPublication of Scientific Results: Open Access Initiative at NU Global Engagement Global Engagement Top Overseas Partner InstitutionsLiaison Professor of Niigata UniversityDatabase for NU International Collaborative ActivityOverseas OfficesInter-University Exchange Project by MEXT Prospective Students Current Students Alumni News Access Contact Us Site Map Language 日本語 English 中文 한국어 Русский HOME News Trends in the incidence of renal replacement therapy due to rapidly progressive glomerulonephritis in Japan, 2006–2021 Trends in the incidence of renal replacement therapy due to rapidly progressive glomerulonephritis in Japan, 2006–2021 Mar 13 2024 A new Japanese nationwide study revealed that from 2006 to 2021, the number of patients with incident renal RRT due to RPGN increased, with an increase in the age-specific incidence of RRT due to RPGN in the older age groups (≥70 years old). Given the increasing trend in the incidence of RRT in older age groups and the ongoing population aging in Japan, the number of patients with incident RRT due to RPGN is likely to continue to increase in the future. "RPGN is clinical syndrome that causes a rapid loss of kidney function, usually within a few days to a few weeks," said Dr. Wakasugi, the corresponding author of the study. "The survival and renal prognosis of Japanese patients with RPGN has improved in recent years. An improved renal prognosis in patients with RPGN would decrease the incidence of RRT due to RPGN, whereas an improved survival may increase the number of patients who progress to end-stage kidney disease (ESKD), resulting in an increase in the incidence of RRT due to RPGN. To date, no study has evaluated the trends in the incidence rates of RRT due to RPGN in Japan." Using data from the Japanese Society of Dialysis Therapy registry and national census, the study revealed that the number and crude rates of patients with incident RRT due to RPGN increased in both sexes. The standardized incidence ratios significantly decreased initially relative to the first period (2006–2009) but gradually increased thereafter. Age-specific incidence rates in the older age groups (≥70 years old) also initially decreased in the period 2010–2013 but increased thereafter, peaking in the period 2018–2021. Given the increasing trend in the incidence of RRT in older age groups and the ongoing population aging in Japan, the number of patients with incident RRT due to RPGN is likely to continue to increase in the future. "Although the exact reasons for these changes are unclear, several advances were made in the diagnosis and treatment of RPGN during the study period in Japan," said Dr. Wakasugi. "For example, evidence-based clinical guidelines for RPGN were first published in Japanese in 2014 with updates in 2017 and 2020 and in English in 2016 and updated in 2021. In addition, many therapeutic agents for RPGN are now covered by insurance in Japan, including rituximab, a chimeric monoclonal antibody targeting the pan-B-cell marker CD20 for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (covered since 2013), plasma exchange for anti- anti-glomerular basement membrane (GBM) nephritis (covered since 2016), and ANCA-associated vasculitis (covered since 2018). Furthermore, RPGN and anti-GBM nephritis have been specified as intractable diseases ("Nanbyo" in Japanese) since 2015 to promote research to clarify the pathogenesis of these diseases and develop pharmaceutical products and medical devices targeting them. These changes may have contributed to the improvement in the survival of patients with RPGN, especially in older age groups, in recent years." Publication Details Journal: Internal Medicine Title: Trends in the Incidence of Renal Replacement Therapy due to Rapidly Progressive Glomerulonephritis in Japan, 2006–2021 Authors: Minako Wakasugi, Ichiei Narita DOI: 10.2169/internalmedicine.3343-23 News release The article was released in EurekAlert, the online publication of the American Association for the Advancement of Science. More News Mar 13 2024 Research results Polygenic effects on the risk of Alzheimer's disease in the Japanese population Mar 06 2024 Research results Uncovering The Cyclization Mechanism of Cyclic β-1,2-Glucan Synthase Feb 29 2024 Research results Discovery of Proteins Associated with the Progression of Dialysis-related Amyloidosis All News About NU About NU Top University ProfilePresident's MessageFacts and FiguresLiving in NiigataBrochures / VideosEmploymentInformation Regarding the COVID-19 and Other Infectious Diseases Study at NU Study at NU Top Flow ChartDegree Programs (Undergraduate)Degree Programs (Graduate)Non-Degree Programs (Research Student)Non-Degree Programs (Exchange Student Program)Niigata University Short-term ProgramJapanese Language ProgramsFees / ScholarshipsStudent LifeCareer SupportSyllabus2024 Orientation for International Students Research Research Top FeatureResearch InstitutesCollaborationFind ResearchersPublication of Scientific Results: Open Access Initiative at NU Global Engagement Global Engagement Top Overseas Partner InstitutionsLiaison Professor of Niigata UniversityDatabase for NU International Collaborative ActivityOverseas OfficesInter-University Exchange Project by MEXT page to top About This Site Privacy Policy Site Map © Niigata University